Clinical trial of Shuganjieyu capsules in the treatment of psoriasis vulgaris
10.13699/j.cnki.1001-6821.2017.03.009
- VernacularTitle:舒肝解郁胶囊治疗寻常型银屑病的临床研究
- Author:
Chun-Feng CHEN
1
;
Yi-Zhi ZHENG
;
Li-Ying JIA
;
Tu-Gen YU
Author Information
1. 浙江中医药大学附属第一医院精神卫生科
- Keywords:
Shuganjieyu capsule;
psoriasis;
Hamilton Depression Scale;
Hamilton Anxiety Scale;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(3):222-225
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of Shuganjieyu capsules in the treatment of psoriasis vulgaris.Methods Sixty patients with progressive psoriasis vulgaris were randomly divided into control group and treatment group with 30 cases per group,and 30 healthy volunteers as healthy control group.The control group was given orally compound glycyrrhizin tablets 50 mg tid,halogen topical betamethasone /triclosan cream and calcipotriol ointment rubbed on the affected area bid.Treatment group was treated with Shuganjieyu capsules 0.72 g tid oral,on the basis of control group.Two groups were treated for 4 courses with 4 weeks per course.The clinical efficacy and adverse drug reactions were compared between two groups.The Hamilton Depression Scale (HAMD) score,Hamilton Anxiety Scale (HAMA) score and the levels of serum norepinephrine (NE),dopamine (DA) and 5-hydroxytryptamine (5-HT) were compared between three groups.Results After treatment,the total effective rates in treatment and control groups were 96.67％ (29/30 cases) and 66.67％ (20/30 cases) with statistically significant difference (P ＜0.01).Before treatment,the main indexes in treatment,control and health control groups were compared:HAMD scores were (21.55 ± 5.62),(20.93 ± 5.57),(8.18 ± 1.98) points;HAMA scores were (17.69 ±4.78),(18.04 ±4.14),(7.44 ±2.12) points;NE were (6.95 ±2.31),(6.78 ± 2.26),(2.09 ± 1.11)μg·g-1;DA were (8.02±2.22),(8.16±2.31),(4.68 ±1.34)μg · g-1;5-HT were (62.67±21.18),(61.88 ± 21.55),(21.15 ± 8.66) μg · g-1,with significant difference (P ＜ 0.01).After treatment,the main indexes in treatment and control groups were compared:HAMD scores were (13.46 ± 3.65),(18.89 ± 3.86) points;HAMA scores were (10.75 ± 2.83),(16.64 ± 3.59) points;NE were (3.25 ± 2.16),(4.78 ± 1.32) μg · g-1;DA were (4.65 ± 1.42),(6.88 ±2.19) μg · g-115-HT were (32.34 ± 10.95),(46.65 ± 20.26) μg · g,with statistically significant difference (P ＜ 0.01).There was no adverse drug reactions occurred in treatment and control groups.Conclusion Shuganjieyu capsule has a definitive clinical efficacy and safety for the treatment of psoriasis vulgaris,which can improve the patient's mental state,and improve peripheral monoamine neurotransmitter levels.
